Clinical Trials Logo
  1. Home
  2. Chronic Myeloid Leukaemia
  3. NCT01475110

Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib — CML0609  

Chronic Myeloid Leukaemia Clinical Trial

Official title:
Observational Study in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia (CML) Treated With Nilotinib: Follow-up of the Italian Patients. GIMEMA Study CML0609

Clinical Trial Summary

The GIMEMA CML Working Party promotes an observational (retrospective and perspective) study of Imatinib-resistant or intolerant CML patients treated with Nilotinib in Italy. Enrollment will include all patients who started Nilotinib between January 2005 and December 2012. Patients will be followed for 4 years since treatment start. After this time, survival data, disease status and treatment will be recorded at 6-months-interval. This study will help the definition of guidelines for a proper management of Nilotinib in any-phase CML patients.

Clinical Trial Description

Follow-up is required until the end of treatment for the purposes of the study for all patients by standard hematologic, cytogenetic and molecular criteria. This study will not contemplate any additional expense beyond what is expected for a regular follow-up, according to the international guidelines for CML. Sample Size: target accrual was not defined, all eligible patients observed between January 2005 and December 2012 will be included. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01475110
Study type Observational
Source Gruppo Italiano Malattie EMatologiche dell'Adulto
Contact
Status Completed
Phase
Start date September 13, 2012
Completion date November 24, 2016
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05682924 - Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib
Completed NCT05286528 - Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database
Active, not recruiting NCT01597219 - Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers Phase 2
Active, not recruiting NCT01699217 - Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase
Completed NCT00390897 - Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia Phase 4
Completed NCT02546375 - A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands
Active, not recruiting NCT01804985 - De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia Phase 2
Completed NCT01343173 - Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib N/A
Completed NCT05893836 - Real-World Disease Management and Outcomes in Chronic Myeloid Leukaemia
Recruiting NCT02001818 - Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia Phase 2
Completed NCT01621724 - WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study Phase 1/Phase 2